title: A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice.
abstract: Respiratory syncytial virus (RSV) belongs to the family Paramyxoviridae and is the single most important cause of serious lower respiratory tract infections in young children, yet no highly effective treatment or vaccine is available. Increased airway resistance and increased airway mucin production are two manifestations of RSV infection in children. RSV rA2-line19F infection induces pulmonary mucous production and increased breathing effort in BALB/c mice and provides a way to assess these manifestations of RSV disease in an animal model. In the present study, we investigated the effect of prophylactic treatment with the F(ab')2 form of the anti-G protein monoclonal antibody (MAb) 131-2G on disease in RSV rA2-line19F-challenged mice. F(ab')2 131-2G does not affect virus replication. It and the intact form that does decrease virus replication prevented increased breathing effort and airway mucin production, as well as weight loss, pulmonary inflammatory-cell infiltration, and the pulmonary substance P and pulmonary Th2 cytokine levels that occur in mice challenged with this virus. These data suggest that the RSV G protein contributes to prominent manifestations of RSV disease and that MAb 131-2G can prevent these manifestations of RSV disease without inhibiting virus infection.
authors.affiliation: Emory University Department of Pediatrics and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
authors.forename: Seyhan
authors.initials: S
authors.lastname: Boyoglu-Barnum
authors.forename: Kelsey A
authors.initials: KA
authors.lastname: Gaston
authors.forename: Sean O
authors.initials: SO
authors.lastname: Todd
authors.forename: Cemil
authors.initials: C
authors.lastname: Boyoglu
authors.forename: Tatiana
authors.initials: T
authors.lastname: Chirkova
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Barnum
authors.forename: Patricia
authors.initials: P
authors.lastname: Jorquera
authors.forename: Lia M
authors.initials: LM
authors.lastname: Haynes
authors.forename: Ralph A
authors.initials: RA
authors.lastname: Tripp
authors.forename: Martin L
authors.initials: ML
authors.lastname: Moore
authors.forename: Larry J
authors.initials: LJ
authors.lastname: Anderson
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000276:immunology; D000914:Antibodies, Viral / Q000008:administration & dosage* / Q000276:immunology; D018890:Chemoprevention / Q000379:methods; D004195:Disease Models, Animal; D005260:Female; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009093:Mucus / Q000378:metabolism*; D012119:Respiration; D018357:Respiratory Syncytial Virus Infections / Q000473:pathology / Q000517:prevention & control*; D012136:Respiratory Syncytial Viruses / Q000276:immunology / Q000472:pathogenicity*; D012137:Respiratory System / Q000473:pathology*; D012141:Respiratory Tract Infections / Q000473:pathology / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D007140:Immunoglobulin Fab Fragments